Could a blood thinner stop deadly liver bleeds? new trial aims to find out

NCT ID NCT07521332

First seen Apr 17, 2026 · Last updated May 12, 2026 · Updated 8 times

Summary

This study tests whether adding the blood thinner apixaban to the standard drug carvedilol can prevent serious complications like bleeding, fluid buildup, and liver failure in people with cirrhosis and high blood pressure in the liver. About 220 adults with stable cirrhosis will receive either apixaban or a placebo, plus carvedilol, and be followed for 12 months. The goal is to see if this combination reduces the risk of liver-related events and death.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asian Institute of Medical Sciences

    RECRUITING

    Hyderābād, Sindh, 71000, Pakistan

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.